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Abstract 
This study tested the effectiveness of special 
packaging in increasing the medication compliance of 
hypertensive patients in the outpatient clinic at San 
Joaquin General Hospital. Seventy patients were randomly 
assigned to an experimental and control group. After a 6 
week treatment period, the mean compliance estimates for the 
experimental and control groups (xl = 68.59%, x2 = 48.67%) 
were compared and found to be significantly different (t = 
2.46, df = 33, p < .05). In addition, a statistically 
significant negative correlation was found between 







Medication compliance, "the extent to which the 
patient's behavior coincides with the clinical prescription" 
(Fletcher, Pappius, & Harper, 1979, p. 635), is the crucial 
link between the doctor's prescription and the healing 
~-
process. If patients ingest a reduced amount of the 
prescribed medication the treatment goal may either not be 
achieved or may be achieved more slowly (Kaplan, 1980). 
Overdosing on medication is also undesirable since "many 
medications carry greater risks from overdosage than 
underdosage" (Rudd, 1980, p. 866). While underconsumption 
of medication has received more attention in the compliance 
literature, overconsumption of medication has been estimated 
to account for 65% of the problems in medication compliance 
;j 
which come to a physician's attention (Swinyard, 1980) • 
~ 
-
Thus, in any discussion on medication compliance it is -
useful to reiterate· that both underdosing and overdosing are 
to be viewed as a deficit in compliance. 
This paper on medication compliance will first present 
a brief literature review on the subject. A proposed 
experiment designed to test the effectiveness of special 
medication packaging on increasing medication compliance in 
hypertensive patients follows. 
Magnitude of Noncompliance 
Estimates of how many people are noncompliant range 
from 11% to 93% (Shope, 1981) with 50% considered typical 
(Sackett & Snow, 1979, Chap. 2). The wide variability in 
3 
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the estimates is caused in part by the different operational 
definitions used for compliance (which vary based on the 
percentage of compliance necessary for a particular 
medication to work in a particular disease). For example, 
in studies on hypertension, patients are classified as 
compliant when 80% of their pill taking behavior coincides 
with the doctor's advice. However, in the case of diabetes, 
- -
administration of insulin must concur 95% of the time with 
the prescription for the blood sugar level to remain under 
control. Other factors which are responsible for the 
variability in compliance estimates include the measures of 
compliance used (e.g., self report, pill count, laboratory 
tests) and conceptual problems with respect to setting the 
cut off point between compliance and noncompliance. For 
example, when a physician prescribes the minimum dosage 
required for therapeutic effects to occur, a high degree of 
medication compliance is more important for the underdosing 
patient than when the physician prescribes more liberally. 
Complications of Noncompliance 
----
~ 
Medication noncompliance can not only thwart the health 
benefits achieved by accurately following a proper 
medication prescription, but can also lead to inappropriate 
medication or surgical recommendations and unnecessary 
testing by physicians who think their treatment 
recommendations are not working. In addition, in the case 
of antibiotics, insufficient use may lead to the development 
4 
of a strain of organisms which is resistant to the 
antibiotic (Matter, Markello, & Yaffe, 1974). 
Measures of Compliance 
~-
Direct Measures 
Analysis of body fluids is the most direct and perhaps 
the most accurate way to measure compliance. Even so, there 
~-
are problems with this method (Gordis, 1979, Chap. 3). 
First, there are technical problems with respect to a test's 
sensitivity and specificity to the presence of the relevant 
medication, its metabolite, or a marker (an inert substance 
added to the medication specifically for the detection of 
compliance). The test may either not be sensitive to or may 
not pick up the presence of the compliance indicator, or it 
may lack specificity to the compliance indicator and give a 
false positive. Second, in carrying out a test, it is 
important to know the absorption and excretion pattern of 
I 
the drug in question so that the test is conducted during 
the critical time for compliance detection. 
Body fluids studied to date for use in compliance 
detection include blood, urine, saliva, sweat, semen, and 
tears (Litt & Cusky, 1980). While blood is useful in the 
detection of medication compliance for anticonvulsants, 
salicylates (e.g., aspirin), digoxin, and theophyllin (for 
asthma), its use is limited because of the necessity to use 
invasive venipuncture techniques which are painful, time 
consuming, require the presence of the patient in the 
5 
doctor's office, and carry the possibility of introducing an 
infection. For these reasons increasing attention has been 
paid to the alternative body fluids such as urine and 
saliva. 
Because of the high cost of quantitative analysis of 
body fluids qualitative analyses have become popular. For 
example, mefenamic and flufenamic acid (to treat arthritis), 
and riboflavin (a vitamin marker) fluoeresce when present in 
urine exposed to ultraviolet light. While the use of six 
mg. of riboflavin as a marker added to each capsule of 
medication seems promising, Scoutter and Kennedy (1974) 
caution against its indiscriminate use. First, false 
positives may be obtained in persons who take multivitamins. 
Second, testing for the presence of a marker does not 
indicate the degree of medication compliance. Third, 
Scoutter and Kennedy point out that a noncomplying patient 
may happen to take medication right before the body fluid 
collection while a usually compliant patient may forget to 
do so. In addition, riboflavin is so readily absorbed and 
excreted by the body that if riboflavin is to be detected in 
the urine, the urine should be inspected within two to three 
hours after the riboflavin is ingested. Finally, riboflavin 
can change the bioavailability of the medication to which it 
is added. Thus, many pharmacists advise against the use of 
riboflavin as a marker. 
Indirect Measures 
The most commonly used indirect measures of compliance 
6 
are pill counts, self reports, outcome assessments, and 
physician estimates. When combined, these measures are 
thought to provide as much information as the more direct 
measures (Litt & Cusky, 1980). 
Pill count. The pill count measure of compliance 
involves the comparison between the number of pills 
remaining in the patient's bottle and the number of pills 
that should have remained. Compliance is reported as the 
number of pills removed during a specific time period 
divided by the number of pills prescribed for that time 
period times 100%. Problems encountered with this approach 
include pharmacist's errors in the filling of the 
prescription (Monson & Bond, 1978), underdosing patients 
throwing away pills in anticipation of the pill count, and 
patients forgetting to make their medication containers 
available for the pill count. Studies which have 
investigated the accuracy of pill counts indicate that pill 
counts overestimate medication compliance by as much as 10% 
(Bergman & Werner, 1963; Roth, Carson & Hsi, 1970). 
Self report. Several investigators have compared self 
reports with pill counts and urine tests. Feinstein, Wood, 
Epstein, Taranta, Simpson, and Turskey (cited in Gordis, 
1979, Chap. 3) compared interview and pill count estimates 
of compliance in penicillin prophylaxis treatment (to 
prevent rheumatic fever). Although both measures had high 
agreement with respect to classifying patients into the poor 
compliance groups, there were marked differences in their 
7 
classification of patients into good and questionable 
compliance groups. The interview method overestimated the 
number of patients classified as having good compliance by 
18%. Chaves (cited in Gordis, 1979, Chap. 3) found negative 
urine tests in 27% of the patients who said they took their 
pills. In 1970, Rickels and Briscoe compared 675 self 
reports with pill counts and again found that self reports 
overestimated compliance. The discrepancy between self 
reports and pill counts was greatest for subjects who were 
only slightly noncompliant. Sheiner, Rosenberg, Marate, and 
Peck (1974) found that average outpatients took only 72% of 
the digitalis tablets they reported they had taken. 
The advantages of using self report include (a) it is 
cheap, (b) those who admit noncompliance rarely lie, (c) if 
the only purpose of the interview is to identify 
noncompliance, ~any will be identified, and (d) patients who 
admit to their noncompliance during an interview respond 
best to interventions (Litt & Cusky, 1980). 
Outcome Assessments. While it is natural to assume 
that compliance to a properly prescribed drug therapy will 
result in a positive outcome, there are many variables 
besides the drug therapy which may affect the outcome (e.g., 
reassurance, stress, sleep, weather, physical health, 
strength of virus or bacteria, and severity of illness, to 
name a few). Therefore, compliant patients may sometimes 
fail to improve promptly while noncompliant patients may 




Briggs, Mutterperl, Adelman, & Creditor (1976). Only 44% of 
the compliant patients achieved controlled blood pressure 
whereas 56% of the compliant patients did not. Furthermore, 
16% of the noncompliant patients achieved blood pressure 
control despite their lack of compliance. 
Gordis (1979) also notes that "the effect of 
noncompliance is highly dependent upon how closely the 
prescribed dosage approximates the minimum dosage required 
for optimal therapeutic effect •••• If for example the 
prescribed dosage substantially exceeds the mimimum effect 
dosage, low compliance may not reduce effectiveness at all" 
(p. 34). 
Physician estimates of compliance. While it may seem 
logical to assume that experienced physicians would be adept 
at estimating their own patients' compliance, studies have 
shown that this assumption is false. Charney, Bynum, 
Eldridge, Frank, MacWhinney, McNabb, Scheiner, Sumpter, and 
Iker (1967) showed that pediatricians' predictions of 
complia.nce were no better than chance. Caron and Roth 
(1968) found that 46% of physicians overestimate compliance. 
They noted that the senior physicians were no better at 
predicting than the junior physicians who in turn were no 
better than the residents. Davis (1966) found that medical 




Determinants of Compliance 
Features of the disease 
Disease characteristics are considered unimportant as 
determinants in compliance (Haynes, 1979, Chap. 4). Less 
~-
than half of the disease factor studies that Haynes, Taylor 
& Sackett (1981) reviewed found significant correlations 
between disease factors and compliance level. The 
exceptions to these are: (a) that psychiatric patients tend 
to be low compliers, (b) the more numerous the symptoms 
possibly the lower the compliance, and (c) increased 
disability may be accompanied by increased compliance. 
Clinical Setting and the Referral Process 
Because attendance at the physician's office and 
medication compliance are related, it is helful to look at 
features of the referral process and clinical setting which 
help the patients to keep their physician's appointments. 
Although there is lack of research in both areas, several 
helpful factors have been determined; (a) the longer the 
time between the referral and the appointment, the lower the 
chances are that the patient will keep the appointment 
(Haynes, 1979, Chap. 4), (b) Hoening and Ragg (cited in 
Haynes, 1979, Chap. 4) found that patients referred to a 
psychiatric clinic were more likely to keep their 
appointment if the referral was to a specific physician, and 
(c) decreasing the waiting time in the clinic may increase 
clinic attendance (Rockart & Hoffman, 1969). 
10 
Features of the Regimen ~--
Getting patients to keep their clinic appointments will 
not necessarily increase medication compliance. There are 
several features of the treatment regimen which also affect 
medication compliance {Haynes, 1979, Chap. 4). They are as 
follows; 
{1) Duration of treatment. Numerous studies have shown 
that the duration of treatment is accompanied by a 
concomitant decrease in medication compliance {Haynes, 1979, 
Chap. 4). 
{2) Complexity. Studies almost unanimously indicate 
that the greater the number of medications prescribed the 
lower the compliance {Haynes, 1979, Chap. 4). However, the 
influence of the frequency of medication in the medication 
~-- --
regimen is not as well understood. Some studies have 
indicated that as the frequency of taking medication 
increases from once a day to four times a day, the 
medication compliance decreases. Other studies have failed 
to support this observation {Haynes, 1979, Chap. 4). 
{3) Side effects. Intuitively speaking, I would expect 
that the greater the number of side effects of taking a drug 
the lower the compliance would be. While some studies which 
cite data for psychiatric patients support this contention, 
the majority of studies have provided evidence which refute 
it {Haynes, 1979, Chap. 4). For example when patients have 
been asked to list their reasons for noncompliance, side 
effects are mentioned only 5% to 10% of the time, and even 
11 
then they are mentioned towards the bottom of the list. 
This finding indicates that while side effects may be 
important when they occur, they are not the most common 
cause of noncompliance. 
~-
(4) Cost. Most studies have demonstrated a negative 
relation between cost and compliance, although a few have 
found no correlation or a positive one (Haynes, 1979, 
Chap. 4) • 
(5) Dispensing. Haynes (1979, Chap. 4) describes a 
controlled study which was carried out on the effects of the 
safety lock on pill containers with respect to compliance. 
The data showed that the safety lock significantly reduced 
medication compliance. Many who did comply reported that 
they had removed the safety container top. 
Mattar, Markello, and Yaffe (1975) found that community 
pharmacists, when filling prescriptions, dispensed less 
medication than was prescribed on 15% of all prescriptions 
for an antibiotic for otitis media. 
Patient characteristics 
(1) Demographics. Studies have generally shown that 
knowledge of a patient's demographic characteristics does 
not help to predict medication compliance (Mathew & Hingson, 
1978). 
(2) Knowledge. While knowledge about a medication 
regimen and disease is helpful, it is not in and of itself 
sufficient to insure compliance (Bergman & Werner, 1963~ 
Sackett, Haynes, Hackett, Taylor, Gibson, Roberts, & 
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Johnson, 1975). Sackett et al. (1975) conducted a study on 
steel workers with newly discovered hypertension in a 
Canadian factory. The hypertensive workers were divided 
into a group which received special instruction concerning 
hypertension and its treatment and a group which did not 
receive any special instruction. While the group members 
which received special instruction concerning hypertension 
scored higher on a quiz testing knowledge about 
hypertension, they were not found to be more compliant than 
the group receiving no special instruction. 
(3) Health belief model. According to the health 
belief model the probability patients will follow medical 
advice is a function of the patients' perceived 
susceptibility to the disease, the perceived severity of the 
disease, and the perceived benefits and barriers related to 
compliance. The model also includes other variables (such 
as motivation, physician-patient interaction, 
characteristics of the regimen, etc.) as influential on 
compliance (Hershey, Morton, Davis, & Reichgott, 1980). 
Several studies testing the model have shown positive 
correlations up to .5 and .6 between the patients' health 
beliefs and feelings and their compliance (Becker, Maiman, 
Kirscht, Haefner, Drachman, & Taylor, 1979, Chap. 6). The 
correlations tend to be higher when the health beliefs are 
compared with concurrent rather than subsequent medication 
compliance, which may suggest a bidirectional relationship 




affect their medication compliance and compliance may 
influence beliefs. 
(4) Locus of control. Locus of control refers to the 
way a person views the events which occur in his/her life. 
Persons with an external locus of control believe that 
whatever happens to them is due to chance, luck, fate, or 
some outside power. On the other hand, persons with an 
internal locus of control believe they are in control of 
what happens (Duke & Cohen, 1975). Several studies have 
supported the contention that internal locus of control is 
significantly related to compliance (Hershey, et al., 1980; 
Duke, et al., 1975, Becker, et al., 1979) although more 
studies need to be conducted. 
(5) Disease denial and rationalization. Podell and 
Gary (1976) suggest that denial or rationalization of a 
medical condition is related to medication noncompliance in 
hypertensive patients. In their study half of the patients 
who failed to take their medication or go to their physician 
appointments presented illogical excuses such as "I knew my 
blood pressure was high so I did not keep my appointment." 
Features of the Doctor-Patient Interaction 
Several features of the doctor-patient relationship 
have been studied, some of which have been shown to have a 
significant impact on patient compliance. Patients' overall 
satisfaction with their care has been repeatedly 
demonstrated to have a positive relation to compliance (Daly 
& Hulka, 1975). When patients' expectations are met, they 
0::0---
~ 
;; ___ _ 
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are more likely to comply (Shope, 1981). As the level of 
medication supervision increases medication compliance 
increases (Haynes, 1979, Chap. 8). Other variables which 
may be related to compliance include the patient's belief in 
the physician's ability and the patient's perception of the 
physician as friendly (Shope, 1981). 
Strategies For Improving Patient Compliance 
-
~here have been several strategies proposed to improve 
patient compliance. Before initiating an attempt to improve 
medication compliance however, Albert Jensen (1979) suggests 
that the experimenter be able to verify that the following 
guidelines have been met; (a) the physician's diagnosis is 
correct, (b) the drug therapy will do more good than harm to 
the patient, and (c) the patient is an informed and willing 
participant. 
Patient Education 
(1) Disease and treatment. Theoretically one would 
hypothesize that patient education would increase medication 
compliance. Research has shown, however, that patient 
education is not a sufficient condition for medication 
compliance to occur (Haynes, 1979, Chap. 8). 
(2) Medication regimen. Patient errors in medication 
can be subdivided into (a) faulty comprehension of 
medication regimen accompanied by medication errors, and (b) 
good comprehension of medication regimen accompanied by 
medication errors. Because studies indicate that medication 




the treatment regimen, it would behoove the health care 
provider to carefully explain the treatment regimen itself, 
to perhaps provide written instructions of the schedule 
(Podell, et al., 1976; Blackwell, 1979), and to ask patients 
to explain the treatment as they understand it to validate 
their comprehension of the treatment. 
Drug Regimen 
Another way to decrease faulty comprehension is to 
simplify the medication itself by reducing the number of 
different medications used and reducing the frequency of the 
medication administrations. Studies which have compared the 
efficacy of the different dose frequencies have all 
indicated that the less frequent regimens are as effective 
as the more frequent regimens (Blackv1ell, 1979). However, 
recent work in juvenile onset diabetes mellitus indicates 
that frequent administration of insulin might be 
advantageous due to its superior control of blood sugar 
levels (Davidson, 1981). 
While it is a common belief that the larger, less 
frequent doses of medication are accompanied by more side 
effects, this has not been supported in the literature to 
date (Blackwell, 1979, Chap. 9). Caution and discrimination 
should nonetheless be observed in prescribing larger doses, 
and side effects should be monitored. 
Tailoring 
Although tailoring has not been studied as an effective 








tailoring a medication to a patient's own schedule 
would increase compliance. For example, Podell and Gary 
(1976) suggest scheduling the ingestion of a diuretic during 
the time of day the patient will have a bathroom at his 
disposal. Norell (1979) found that medication compliance 
was greatly improved in subjects who were given an education 
and medication tailoring program. 
Parenteral Drug Administration 
Numerous studies have shown that whenever injections 
can be given by the health care provider, patient compliance 
increases (Haynes, 1979, Chap. 8). The low rate of 
compliance found in diabetics who are prescribed daily 
injections of insulin underscores the importance of the 
health care provider's role in the drug administration 
~ --
rather than the injection itself. 
Extended Supervision 
The concept of extended supervision involves such 
things as frequent clinic visits, making home visits, using 
outreach clinics to reach those who might otherwise fail to 
go to the doctor, and adding an extra person to the health 
-
~ 
care team to supervise the patients' use of their 
medications. 
Many studies demonstrate the effectiveness that 
extended supervision has on medication compliance, though it 
is difficult to separate the effects of supervision from 
patient education and counseling (Haynes, 1979, Chap. 8). 
17 
Patient Involvement and Behavior Modification 
Such behavior modification techniques as (a) positive 
reinforcement, (b) negative reinforcement (Azrin & Podell, 
1969), (c) security-deposit contingency contracts, (d) self 
monitoring (Epstein & Masek, 1978), and (e) contingency 
management (Lowe & Lutzker, 1979) have been used 
successfully to increase compliance. Haynes (1979, Chap. 8) 
-~ -
comments that while many of these techniques would be 
difficult and expensive to implement in a private office, 
they do demonstrate the effectiveness of the principle 
involved. 
Attendance at the doctor's office is positively 
correlated with medication compliance (Haynes, 1979, 
Chap. 8). To encourage clinic/office attendance, such 
~ -
procedures as calling patients or sending them reminders of 
their scheduled appointments have been effective. In 
addition, reducing the time patients have to wait in the 
office before they see the physician has also been shown to 
increase medication compliance (Rockart et. al., 1969). 
Medicine Packaging 
Special medication packaging works as a discriminative 
stimulus or cue for appropriate pill taking behavior. Such 
packages are designed so that patients can see when each 
pill should be taken and if a particular pill has been 
taken. One of the most attractive features of this approach 
is that it is time efficient, i.e. the packaging effects a 
maximal response to medication compliance with a minimal 
18 
intervention. This approach works around such difficult 
variables to control as physician-patient interaction and 
relationship, medication regimen, and patients' health 
beliefs. For these reasons special medication packaging 
will be used in the proposed study. Several studies have 
been conducted to determine the effectiveness of special 
pill containers and daily reminders (Demetral, Gipson, 
Irwin, Anderson, & Catania, 1981; Eshelman, & Fitsloff, 
1976; Gazzar, 1978; Linkewich, Catalano, & Flack, 1973; 
Rehder, McCoy, Blackwell, Whitehead, & Robinson, 1980). The 
effectiveness of such special pill containers has been 
repeatedly demonstrated with psychiatric medications (see 
Weber, Demetral, Anderson, Gipson, & Catania, 1978, for more 
information), but research conducted with other disease 
populations has been inconclusive. 
For example, the beneficial treatment effects of the 
special medication packaging were clearly demonstrated in 
the short term study conducted by Linkewich, et al. (1973) 
on penicillin compliance although a second treatment 
variable, an instruction card, was added to the package. 
This instruction card could have interacted with the special 
packaging to enhance its effectiveness. 
Eshelman et al. conducted a study with hypertensive 
patients in 1976. In this study the special medication 
packaging alone was compared to a control group who received 
their medication in regular vials. The results were 







medication compliance had increased, the pill count showed 
very little change. There are several possible explanations 
of what occurred. Most likely (a) the diuretic measured in 
the urine assay, chlorthalidone, gave an overestimate of 
medication compliance due to its long half life, (b) several 
subjects given the special treatment package continued to 
take their medication out of the vials at least part of the 
time. If this occurred, medication compliance as measured 
by the pill count of the special package was underestimated. 
Thus, an average or summation of the two estimates would 
probably have yielded the most accurate estimate. When I 
averaged the results, 65% of the patients receiving their 
medication in the bottles were compliant versus 78% of the 
patients receiving their medication in the special 
packaging. However, when the data was submitted to a chi 
square analysis the difference between the two group's 
proportions of compliant patients was not statistically 
significant. Thus, the special medication packaging was ·not 
shown to increase medication compliance in this case. 
Rehder et al. (1980) conducted a three month study on 
hypertensive patients. One hundred subjects were assigned 
randomly to one of four groups: (a) the control group, (b) 
the disease and medication counseling group, (c) special 
medication container group, and (d) the special medication 
container and counseling group. Compliance was measured by 
a pill count. A problem with the study was that only 64% of 




their pill containers for a pill count. It would seem 
likely that the patients who brought their pill containers 
in would tend to be the most compliant in taking their 
medication. It is not surprising, then, that the medication 
compliance estimate obtained by the pill count was very high 
across all four treatment groups (greater than 85%), and 
that there were no significant differences between treatment 
-~ 
groups. However, when the percentage of patients who had 
greater than 95% medication compliance was compiled for each 
group, the counseling and special medication container group 
and the special medication container alone group had a 
significantly greater proportion of 95% compliance patients 
than either the counseling alone or control groups. In this 
study the subjects' blood pressures in each treatment group 
were also noted. That blood pressure changes did not 
reflect the differences in medication compliance is not 
surprising since once a patient is over 80% compliant in the 
ingestion of antihypertensive medication, other variables 
are considered to be more important in lowering blood 
pressure (such as salt intake and amount of antihypertensive 
medication prescribed). 
Thus, while the effectiveness of the special medication 
packaging has been demonstrated with psychiatric 
medications, its effectiveness with nonpsychiatric 
populations needs more empirical support. A nonpsychiatric 











Hypertension (high blood pressure) is a serious 
disorder which affects 15% to 25% of adults in the United 
States (Williams, Jagger, & Braunwald, 1980). There are 
four plausible end-organ effects associated with 
hypertension if left untreated: (a) kidney failure due to 
glomerularsclerosis (scarring of the glomerula in the 
kidneys which filter poisons out of the blood), (b) heart 
failure due to left ventricular hypertrophy, (c) cerebral 
hemorrhage, (d) atherosclerosis which may lead to a 
myocardial infarction or a stroke. 
Medications used to treat hypertension are divided into 
three classes or "steps", with each step associated with 
increasing risks for side effects. Step I medications 
include diuretics and are the treatment of choice of a 
person with newly discovered hypertension or borderline 
hypertension. If a step I treatment does not lower the 
blood pressure enough, step II drugs such as beta blockers 
and central acting drugs are added. Finally, if neither 
step I or step I and step II drugs used together are 
sufficient, a step III treatment, vasodilators, may be tried 
in addition to the step I and step II drugs. Vasodilators 
reduce blood pressure by acting directly on the constricted 
vessels thereby expanding them so as to reduce the pressure. 
While properly prescribed and taken antihypertensive 
drug therapy is usually effective in reducing blood 
pressure, noncompliance is a common problem. For example, 
22 
in Sackett's 1975 study conducted on hypertensive steel 
workers he and his associates found that only 48% of the 
patients in the control group were compliant in taking their 
medications. Only 53% of patients receiving extensive 
training on hypertension and its treatment were classified 
as compliant at the end of the six month experiment. 
Sackett et al. concluded that instructional strategies 
''fri.volving more direct attempts of behavior modification" 
were more likely to be successful (p. 1207). Lowenthal, 
Briggs, Mutterperl, Adelman, and Creditor (1976) found that 
50% of the patients in their study were compliant. 
Explanations of low compliance in hypertensives include 
(a) hypertensive patients are usually asymptomatic and thus 
have difficulty believing that they are "sick" and need to 
take medication, (b) the medication is expensive, (c) the 
medication has potential side effects which range from 
dizziness, weakness, and headaches, to depression, potassium 
depletion, and exacerbation of asthma and heart failure 
(Williams, Jagger, & Braumwald, 1980), (d) the medication 
does not cure the cause of hypertension - thus patients are 
put on a long term drug regimen indefinitely, (e) patients 
on more complex drug regimen get confused with respect to 
when to take each medication, (f) patients forget if they 
have taken their medications. Each of these explanations 
for noncompliance has been discussed earlier in the paper 





What remained to be shown is that special medication 
packaging could indeed increase medication compliance in 
hypertensive patients. The special medication packaging 
works as a discriminative stimulus or cue for appropriate 
pill taking behavior. To this end the packages are designed 
so that the patient can see when each pill should be taken 
and if a particular pill has been taken. Because of its 
form the special packaging addresses two of the previously 
mentioned explanations for medication noncompliance - when 
to take the pills and if a particular pill has or has not 
been taken. 
To adequately demonstrate the effectiveness of the 
special medication packaging, a study was carried out that 
controlled variables which might either challenge the 
study's internal or construct validity or otherwise make the 
results of the experiment hard to evaluate. The following 
suggestions were integral to the study described throughout 
the rest of the paper: 
(1) Select a group of hypertensive patients who are 
judged to be capable of self administration of medication. 
(2) Where applicable, prescribe hydrochlorothiazide 
(HCTZ) or dyazide to patients who need to take a diuretic 
because the thiazides are easily detected in the urine. 
Hydrochlorothiazide is preferred over chlorthalidone because 
it has a shorter half life (2.5 hours versus 44 hours). 
Thus detection of its presence in the urine indicates that 




period. On the other hand, the presence of chlorthalidone 
indicates that medication has been ingested within the past 
48 to 72 hours. Because the antihypertensive medication 
regimen is a daily one, hydrochlorothiazide gives a more 
accurate estimate of medication compliance (Benet & Sheiner, 
1980}. Urine specimens should be collected within four 
hours after the ingestion of the medication to insure the 
detection of the medication's presence. 
(3} Offer the special treatment package alone to an 
experimental treatment group and compare the medication 
compliance to a control group whose drugs are dispensed in 
regular pharmceutic vials. 
(4} Use nonreactive routine tests to estimate 
medication compliance (e.g. urine samples, blood pressures} 
in order to avoid such reactive patient responses as "the 
guinea pig effect" (Webb, Campbell, Schwartz, & Grove, 1981, 
p. 49} where patients change their usual behavior (such as 
medication compliance} due to their awareness of being 
observed. By using measures that the patients are familiar 
with the guinea pig effect can be avoided. 
(5} To increase the probability that the patients 
assigned to the special medication packaging group 
discontinue using their old pills in the vials, several 
months before the experiment begins the physicians 
participating in the study should be asked to prescribe only 
the number of pills that the patients estimate they need in 











The 70 patients who qualified to participate in the 
study were referred by three hospital resident physicians 
and one staff physician. Criteria for selection included: 
(1) an untreated diastolic blood pressure greater than 
90 mm Hg or systolic blood pressure greater than 145 mm Hg. 
12) · ~ap~bllity to administer medication to one's self. 
(3) exclusive use of the hospital pharmacy to fill 
antihypertensive medication prescriptions. 
(4) being a patient of a physician who agreed to 
follow the guidelines of our study as listed below. 
Treatment Conditions 
The 70 patients were randomly assigned to the two 
treatment groups of the posttest-only control group design: 
(1) Group I, which received the special pill 
containers and a posttest. 
(2) Group II, which received the regular pill 
containers and a posttest. 
Patients were assigned so that each group would have 
approximately the same number of patients receiving Step I 
treatment (only diuretics), Step I & Step II treatments, and 
Step I, II, and III treatments. All patients were seen by 
their doctor on at least one occasion prior to the beginning 
of the study. After repeated rescheduling of clinic 
appointments we were able to get only 48 patients to come to 
~~ 
§-~-
~- _: __ 
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26 
the first clinic appointment of the study. Of these 48, 
72.9% or 35 came to the second scheduled clinic appointment. 
The second clinic visit was not rescheduled if missed 
because the number of pills prescribed during the first 
visit matched the number of days between the scheduled 
appointments. Thus, pill counts and urine assays would 
necessarily be affected by an extension between the first 
-
and second clinic visits. 
The demographic characteristics of the 35 patients who 
remained in the study are similar to those who dropped out 
(see Table I for a comparison). About a third of the 
patients were white, a third black, and a third were of 
Mexican or Oriental descent. About a third of the patients 
were married, about a fourth were widowed, and the remaining 
patients were single, separated, or divorced. Only 2 of the 
35 patients' expenses were covered by a third party (i.e. 
insurance). Nine patients were classified as private (i.e. 
having no funding other than their own) and 24 patients' 
medical expenses were covered by government sources (i.e. 
Medi-Cal and Medi-Care). The patients who remained in the 
study did not differ significantly with respect to 
demographic characteristics from the subjects who dropped 
out. 
Of the 35 patients lost in the study it is known that 
one was hospitalized for a myocardial infarction, another 
was hospitalized for coronary bypass surgery, two moved out 







Table I. Summary of Demographic Characteristics of Study Subjects 
versus Drop Out Subjects and Experimental versus Control Subjects 
Demographic Study Drop Out Experimental Control 
Characteristics Subjects Subjects Subjects Subjects 
N=35 N=35 N=l4 N=21 
Age Mean 59.77 54,80 58.79 60.43 
Standard Deviation 14.53 13.33 15.03 14.53 
Race White 11 14 3 8 
Mexican 5 8 3 2 
Black 14 12 7 7 
Oriental 5 1 1 4 
Harital Single 4 4 2 2 
Status Married 14 18 7 7 
Widow 9 5 4 5 
Separated 2 4 0 2 
Divorced 6 4 1 5 
Payment Medicare 3 1 2 1 
Medicare/ 
11 6 4 7 Medi-cal 
Private 9 11 3 6 
Medi-cal 10 15 4 6 
3rd Party 2 2 1 1 
Doctor Young 18 15 8 10 
Formoso 4 4 2 2 
Vaughan 6 12 2 4 
Renal 7 4 2 5 
City Stockton 30 21 12 18 
Lathrop 0 1 0 0 
French Camp 0 3 0 0 
Galt 0 1 0 0 
Linden 1 0 1 0 
Tracy 1 1 1 0 
-· 
Manteca 2 4 0 2 












patients became angry and left before seeing their physician g--
-~-
~ 
after waiting in the clinic office for over an hour, and one ~~ 
experimental patient was mistakenly given her medication in 
vials at the pharmacy. 
Of the 35 subjects who were followed throughout the 
study, 14 were in the experimental group and 21 were in the 
control group. As can be seen in Table I, the demographic 
characteristics are approximately equivalent between the 
experimental and control groups. 
Special Pill Containers 
The special pill containers were equivalent to the 
Medi-Dose containers used by Demetral et. al., (1981) in 
their study on medication compliance. The prescribed anti-
hypertensive pills were placed individually in plastic 
compartments on medication cards clearly labelled for the 
time of day each pill should be taken. There was a new 
medication card or container for each day of the regimen, 
and these pill containers were given to patients in the 
correct order of their intended use. It should be noted 
= ----
" 
here that special medication packaging has been described as ~------'--=---
difficult to open (Eshelman & Fitzloff, 1976). Thus the 
special medication packages probably did not enjoy an unfair 
advantage over the safety-cap prescription vials with 
respect to the ease in which the containers were opened. 
Procedure 
Physician guidelines. 
(1) The patients' second clinic appointment was six 
29 
weeks after the first appointment. 
(2) Medication prescriptions covered the six week 
interval between clinic visits. 
(3) If the patient was on a beta blocker, the 
patient's pulse was taken at the final clinic appointment. 
(4) Urine samples were collected on the day of the 
second clinic visit. 
(5) Special medication packaging patients were told 
that their antihypertensive medication would be dispensed in 
different containers and that the patients should 
temporarily discontinue their "old" medication. 
(6) All patients were reminded to bring in their 
medication on their next scheduled visit. The reminder came 
in the form of telling the patients not to forget and giving 
the patients a written reminder with the date of the next 
scheduled visit. 
Pharmacist guidelines. Patients in the control group 
received their medication as usual in the safety-cap 
prescription vials from the hospital pharmacists. As is 
customary, the hospital pharmacists briefly explained the 
medication regimen (i.e. read the vial label). Patients in 
the special medication container group received their 
medication at the hospital pharmacy in the special 
medication packages with the same explanation of the 





pharmacists briefly explained how to use the packaging. 
In order for the experiment to have high internal validity 
(which means that the experimental results are due to the 
manipulation of the treatment variables), both the special 
packaging group and the control group received the same 
treatment in all respects as much as possible, except for 
the special packaging. Thus the pharmacists gave the 
control group the same amount of time and attention as they 
gave to the special packaging group. 
The pharmacists were requested to be brief and 
nonjudgmental in their explanations concerning the new 
packages and to explain that the hospital was just trying 
them out. Giving additional information was avoided. 
Nurse guidelines. The nurse completed her routine duty 
of taking each patient's blood pressure before the patient 
saw the doctor. In addition, the nurse requested the 
patients to provide her with a urine sample while they were 
waiting in the clinic to see the doctor. 
Dependent Measures of Compliance 




presence of hydrochlorothiazide in the urine 
resting pulse at clinic visits for patients taking 
beta blockers 
(3) the blood pressure reading at clinic visits 
(4) the pill count at each clinic visit 
~- -
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(5) the blood pressure reading at any emergency room 
visit during the study period 
A special attempt was made to use nonreactive 
measures as recommended by Webb, Campbell, Schwartz, and 
Grove (1981) so that the estimates of compliance would be 
more accurate. The raw score obtained on each measure for 
each subject was assigned the number of points suggested by 
a table of weighted scores which was constructed before the 
study began (see Appendix A for the listing). One dependent 
measure was dichotomous (the presence or absence of 
medication in the urine) while other measures estimated 
several levels of compliance. Each subject was assigned a 
percentage compliance score by adding up the total number of 
points earned and dividing that sum by the total number of 
points possible for that individual. Once each subject was 
assigned a score, the mean percentage compliance score and 
standard deviation for all the subjects was calculated and 
the mean percentage compliance scores for the special 
packaging treatment group and the control group were 
compared with a t-test. In addition the means for each 
individual compliance measure were compared using the raw 
scores when possible. 
Detection of medication in the urine. Lowenthal, 
Briggs, Mutterperl, Adelman, and Creditor (1976) describe a 
test for the detection of thiazide diuretics (such as 
hydrochlorothiazide and dazide) in the urine which yields 







drug rather than quantity). Urine specimens of patients who 
are prescribed thiazides were subjected to this test and 
were scored as follows: for the detection of any amount of 
thiazide in the urine, 10 points were assigned. 
Resting pulse. If blood pressure control is not 
achieved by diuretics alone, beta blockers (a step II 
treatment) may be added. The beta are receptors of the beta 
part of the sympathetic nervous system. There are beta 
receptors located in the heart. When these are stimulated, 
there is an increase in heart rate and ultimately an 
increase in the blood pressure. The role of the beta 
blockers, then, is to block the beta receptors from 
responding to stimulation by the sympathetic nervous system 
and thus slow down the heart rate and decrease the blood 
pressure. The beta blocker propranolol was used in this 
study. The resting pulse of patients taking beta blockers· 
was measured at the second clinic visit. If it was less 
than 80 beats per minute, the patient received 8 points. If 
it was between 80 and 90, 4 points was assigned. If it was 
greater than 90, no points were assigned. 
Blood pressure. The blood pressure was also measured 
at each clinic visit as an indication of the patients' 
medication compliance. While this measure, as discussed 
earlier, is far from perfect, successful blood pressure 
control is indicative of medication compliance and an 
extremely high blood pressure (greater than 110 diastolic or 







for this measure can be found in Appendix A. 
Pill count. The pill count measures of compliance 
involves the comparison between the number of pills 
remaining in the patient's bottle and the number of pills 
that should have remained. Consumption is reported as the 
number of pills removed during a time period being measured 
divided by the number of pills prescribed for that time 
period times 100%. See Appendix A for scoring. 
Emergency room visits. During the study period we 
expected that some of the patients in our group would visit 
the emergency room in regards to a minor medical problem. 
Since it is routine at the emergency room to have one's 
blood pressure measured and recorded upon requesting 
treatment, we decided that in the event that some of our 
study patients would visit the emergency room we would 
obtain and use their blood pressure as a nonreactive measure 
of compliance. ~ve believe that the emergency room blood 
pressure was more likely to reflect the true degree of 
compliance than the clinic blood pressure because 
underconsumers could not easily "prepare" for an emergency 
by abruptly taking their medications as they might for a 
routine clinic visit. The scoring of the blood pressure 
readings taken at the emergency room was somewhat different 
than the clinic blood pressure readings since emergency room 
visits by nature are more stressful, and therefore more 






The combined measures of compliance indicate that the 
experimental group X= 68.59% was more compliant in taking 
medication than the control groupx = 48.67% (t = 2.46, df = 
33, p <_.OS). This difference of 20 percentage points is a 
42% improvement in score. Although most individual measures 
of compliance suggest that the experimental group was more 
compliant than the control group, none of the individual 
measures of compliance were able to differentiate the 
experimental group from the control group at a statistically 
significant level. The mean values for each of the measures 
used are presented in Table II. 
Because the purpose of antihypertensive medication is 
to lower blood pressure, this measure of compliance was 
examined more closely than the other measures. 
A statistically significant negative correlation was 
found between the combined compliance measures (minus the 
blood pressure measure) and the combined systolic and 
diastolic blood pressure of all the subjects (r = -0.51, E< 
.01). However, no statistically significant difference was 
found between the experimental and control groups' blood 
pressure (combined or diastolic) at the end of the six week 
treatment interval. 
Over the six week treatment interval the experimental 
groups' combined blood pressure (Xl = 232.71, ~2 = 229.07) 
dropped an average of 3.64 points per person while the 
control group's combined blood pressure reading (X1 = 
E= 
--; 




Table II. Summary of Individual and Combined Estimates of Medication Compliance 
in the Esperimental and Control Groups · 
Individual Measures 
Clinic Blood Pressure 
combined systolic and diastolic (mm Hg) 
diastolic (mm Hg) 
Pulse (beats per minute) 
Pill count (percent of pills taken) 
Urine (+ denotes detection. of HCTZ) 
Emergency room blood pressure 
systolic (mm Hg) 
diastolic (mm Hg) 
Overall Percent Compliance Estimate 
(Combined Heasures) 
I 'llillllr::lli'llnmml·· 























































224.19, X2 = 228.67) increased an average of 4.48 points per 
person. These changes in blood pressure were not found to 
be statistically significant at the p = .05 level. 
Discussion 
The use of multiple measures of compliance has proved 
useful in this study. While most individual measures of 
compliance suggested that the special medication packaging 
increased medication compliance, no measure alone 
demonstrated a statistically significant difference between 
the experimental and control groups. By combining a variety 
of measures we were able to approach the construct of 
compliance from several angles and thus obtain a more 
accurate estimate of the true compliance rate of each group. 
Just as data on individual subjects in an experimental 
and control group do not always point to the general pattern 
of results, the data we obtained on the individual measures 
of compliance varied from the general pattern which emerged 
when data from all the measures were summated. The pill 
count provided a maximum estimate of compliance whereas the 
urine assay provided a minimal estimate. This occurred 
because each individual measure (just as each individual 
patient's data) is subject to error. The pill count was 
likely an overestimate of compliance due to it's reactive 
nature (asking the patients to bring the pills in and 
providing them with a written reminder). Other possible 










requested, the experimenter counting the pills accurately, 
and the most compliant patients "remembering" to bring their 
pills in. A different type of error is hypothesized to have 
affected the detection of HCTZ in the urine. In an effort 
to obtain a nonreactive measure of compliance, patients were 
not warned ahead of time that a urine sample would be taken 
at the second clinic visit. Instead, nurses requested the 
samples as soon as the patient reported to the clinic on the 
day of their second appointment. However, most patients 
voided minutes prior to checking in. Since the half life of 
HCTZ is 2.5 hours, and patients were scheduled to check in 
approximately four hours after ingestion, it was important 
to obtain the earliest urine sample possible. Patients who 
voided just prior to the clinic visit had probably excreted 
most of the medication. Thus, when the nurses requested 
urine samples, there was little medication left to excrete. 
Another possible source of error includes the sensitivity of 
the HCTZ detection test: The test we used may not have 
picked up the presence of HCTZ. 
Though blood pressure was negatively correlated with 
compliance across all subjects, there was no statistically 
significant difference found between the blood pressure 
measures or changes in measures in the experimental and 
control groups. Several reasons are postulated: 
(1} all subjects had been receiving treatment for 
hypertension when the study began (i.e. no newly discovered 






blood pressure in both groups were already under fair 
control at the beginning of the study. 
(2) factors other than compliance may affect blood pressure 
(e.g. appropriateness of drug, the dosage level, and diet). 
(3) A period of six weeks may not be of sufficient duration 
for the blood pressure to fully respond to the increased 
rate of compliance caused by the special packaging. 
(4) A sample size of n = 14 experimental subjects may have 
not provided enough power to detect the effect that 
increased medication compliance has on blood pressure. 
An attempt was made to use nonreactive measures in this 
study. All measures with the exception of the pill count 
appeared to meet this goal (no one questioned the reason why 
any measure was taken with the exception of the pill count). 
When patients were requested to bring their pills to the 
second clinic appointment of our study, many asked why. 
Several comments indicated that the patients knew why we 
wanted them to return with the pills (e.g. "You want to see 
if I take my pills, huh?"). Since the pill count was so 
reactive it is not surprising that of all the compliance 
measures the pill count gave the highest estimates for both 
the experimental and control groups. 
This study has demonstrated the effectiveness of the 
special medication packaging in increasing compliance rates 
in hypertensive patients on a short term basis. New studies 
need to be carried out which can demonstrate the 










term basis. If the packaging is found effective over a 
period of several months, it is probable that statistically 
significant drops in blood pressure in comparison with a 
control group will result, thus making the cost of packaging 
justifiable. New populations of subjects (e.g. diabetics, 
patients with congestive heart failure; private office and 
family practice patients) need to be studied to demonstrate 
the effectiveness of the special medication packaging across 
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Point system for quantifying the measures of compliance 
Measurement Points 
(1) Detection of hydrocholorothiazide in the urine 10 
(2) Blood pressure reading at the clinic visit: 
(a) both systolic less than or equal to 
145 and diastolic less than or equal to 90 10 
(b) both systolic less than or equal to 
170 and diastolic less than or equal to 100, 
but either systolic greater than 145 or 
diastolic greater than 90 [If both are 
equal to maximum value (170, 100), score 0] 4 
(c) either systolic greater than 170 or 
diastolic greater than 100 or both equal 170 
& 100 0 
(3) Resting pulse: 
(a) less than 80 per minute 8 
(b) between 80 and 90 per minute 4 
(c) greater than 90 per minute 0 
(4) Pill count at clinic visit: 
(a) relfects taking better than 90% of 
medication 10 
(b) relfects taking between 80% and 
90% of medication 5 
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(5) Blood pressure reading at any emergency room visit: 
(a) both systolic less than or equal 
to 145 and diastolic less than or equal to 90 
(b) either systolic greater than 145 or 
diastolic greater than 90, but both systolic 
less than or equal to 160 and diastolic less 
than or equal to 100 
(c) either systolic greater than 160 or 
diastolic greater than 100 but both systolic 
less than or equal to 190 and diastolic less 
than or equal to 110 
(d) either systolic greater than 190 or 
diastolic greater than 110 
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